Johnson & Johnson JNJ OTHER NEUROSCIENCE — Percent Change (as a percent)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Johnson & Johnson in its filing.
Tagged under the XBRL concept jnj:PercentageChangeInSalesBySegmentOfBusiness.
The official record: Johnson & Johnson’s 10-Q, filed July 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Johnson & Johnson's other neuroscience — percent change (as a percent).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Johnson & Johnson's OTHER NEUROSCIENCE — percent change (as a percent)?
- Johnson & Johnson (JNJ) reported OTHER NEUROSCIENCE — percent change (as a percent) of -14% in Q2 2026.
- How has Johnson & Johnson's OTHER NEUROSCIENCE — percent change (as a percent) changed year-over-year?
- Johnson & Johnson's OTHER NEUROSCIENCE — percent change (as a percent) decreased by 66.7% year-over-year, from -8.4% to -14%.
- What is the long-term trend for Johnson & Johnson's OTHER NEUROSCIENCE — percent change (as a percent)?
- Over 2 years (2021 to 2024), Johnson & Johnson's OTHER NEUROSCIENCE — percent change (as a percent) has grown at a 92.9% compound annual growth rate (CAGR), from 17.2% to -64%.
- What does OTHER NEUROSCIENCE — percent change (as a percent) mean?
- This metric measures the period-over-period percentage growth or decline in net sales for the company's secondary neuroscience product segment. It provides a normalized view of the segment's momentum, allowing for an assessment of how quickly these specific neurological therapies are gaining or losing market share. This growth rate is a key indicator of the segment's trajectory and its contribution to the company's overall revenue expansion.